Zacks Investment Research upgraded shares of Halyard Health (NYSE:HYH) from a hold rating to a strong-buy rating in a research note published on Thursday. Zacks Investment Research currently has $62.00 price target on the medical instruments supplier’s stock.
According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “
A number of other research analysts have also recently commented on the company. KeyCorp raised Halyard Health from a sector weight rating to an overweight rating in a research note on Thursday, April 5th. ValuEngine raised Halyard Health from a hold rating to a buy rating in a research note on Wednesday, February 28th. Stifel Nicolaus increased their target price on Halyard Health from $52.00 to $58.00 and gave the company a buy rating in a research note on Thursday, May 3rd. Morgan Stanley increased their target price on Halyard Health from $48.50 to $52.00 and gave the company an underweight rating in a research note on Thursday, May 3rd. Finally, Deutsche Bank increased their target price on Halyard Health from $42.00 to $50.00 and gave the company a buy rating in a research note on Thursday, May 3rd. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $56.80.
Shares of HYH stock opened at $53.47 on Thursday. The company has a current ratio of 3.22, a quick ratio of 2.96 and a debt-to-equity ratio of 0.43. Halyard Health has a 52-week low of $35.79 and a 52-week high of $54.46. The firm has a market capitalization of $2.53 billion, a P/E ratio of 22.75, a price-to-earnings-growth ratio of 3.42 and a beta of 1.62.
Halyard Health (NYSE:HYH) last issued its quarterly earnings data on Wednesday, May 2nd. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.59. Halyard Health had a return on equity of 7.90% and a net margin of 7.72%. The company had revenue of $156.40 million for the quarter, compared to the consensus estimate of $155.08 million. During the same quarter last year, the business posted $0.48 earnings per share. The firm’s revenue was up 7.3% compared to the same quarter last year. analysts predict that Halyard Health will post 1.77 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Manhattan Co. grew its stake in shares of Halyard Health by 595.1% during the fourth quarter. First Manhattan Co. now owns 15,189 shares of the medical instruments supplier’s stock valued at $701,000 after buying an additional 13,004 shares during the last quarter. Swiss National Bank grew its stake in shares of Halyard Health by 2.3% during the fourth quarter. Swiss National Bank now owns 78,700 shares of the medical instruments supplier’s stock valued at $3,634,000 after buying an additional 1,800 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Halyard Health during the fourth quarter valued at about $385,000. Suntrust Banks Inc. bought a new position in shares of Halyard Health during the fourth quarter valued at about $330,000. Finally, Millennium Management LLC grew its stake in shares of Halyard Health by 107.7% during the fourth quarter. Millennium Management LLC now owns 215,689 shares of the medical instruments supplier’s stock valued at $9,961,000 after buying an additional 111,849 shares during the last quarter. 90.51% of the stock is currently owned by institutional investors and hedge funds.
About Halyard Health
Halyard Health, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.